Developing small molecules to target faulty RNA structures in diseases

Design of Precision Small Molecules Targeting RNA Repeating Transcripts to Manipulate and Study Disease Biology

NIH-funded research University of Florida · NIH-11090350

This study is exploring new tiny molecules that can specifically target and fix faulty RNA structures linked to various diseases, aiming to offer better treatment options for people with neuromuscular diseases and certain types of dementia.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionUniversity of Florida NIH-funded
Lab location1 site (Gainesville, United States)
Project IDNIH-11090350 on NIH RePORTER

What this research studies

This research focuses on creating small molecules that can selectively target and manipulate malfunctioning RNA structures associated with various diseases. Current treatments often rely on oligonucleotides that can only target specific RNA sequences, which limits their effectiveness for many conditions caused by complex RNA structures. By designing small molecules that recognize these structures, the research aims to provide a more universal treatment approach for multiple diseases, particularly those related to RNA repeat expansions. This innovative method could potentially improve therapeutic options for patients suffering from neuromuscular diseases and genetically defined dementia.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with neuromuscular diseases or genetically defined dementia caused by RNA repeat expansions.

Not a fit: Patients with diseases not related to RNA malfunction or those without the specific RNA repeat expansions may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new treatments for over 30 incurable neuromuscular diseases and genetically defined dementia.

How similar studies have performed: Previous research has shown success in targeting RNA structures with small molecules, indicating a promising avenue for further exploration.

Where this research is happening

Gainesville, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions autism-fragile X (AFRAX) syndrome
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.